相关实验视频

Updated: Sep 15, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

静脉注射环胺,mycophenolate mofetil和tacrolimus作为狼性炎的诱导疗法的比较疗效:一个随机对照的开放标签试验

Alekhya Amudalapalli¹, Rasmi Ranjan Sahoo¹, Ashlesha Shukla¹

¹Department of Clinical Immunology and Rheumatology, Institute of Medical Sciences & SUM Hospital, Bhubaneswar, India.

|July 14, 2025

概括

塔克罗利木斯 (TAC) 在狼性炎 (LN) 诱导疗法中与环胺 (IV CYC) 和菌酸莫菲蒂尔 (MMF) 不逊色. 在这项为期一年的研究中,所有治疗方法都显示出可比的安全性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
类风湿病学类风湿病学
免疫学免疫学免疫学

背景情况:

狼性炎 (LN) 是系统性红斑狼 (SLE) 的严重并发症.
有效的诱导疗法对于管理LN和预防损伤至关重要.
环胺 (IV CYC),甲酸莫菲蒂尔 (MMF) 和塔克罗利 (TAC) 是潜在的诱导剂.

研究的目的:

为了比较IV CYC,MMF和TAC作为狼炎诱导治疗的疗效和安全性.
为了确定TAC是否与IV CYC和MMF在24周实现脏反应方面不劣.

主要方法:

一个随机的,开放的,非劣势的,主动对照的研究.
82名LN患者 (≥10岁) 接受了IVCYC,MMF或TAC治疗1年.
主要结局: 24 周的反应 (完全或部分).

主要成果:

在24周,脏反应率为53.5% (IV CYC),66.6% (MMF) 和62.9% (TAC).
据证明,TAC与IV CYC和MMF没有劣势 (p = .58).
在所有组中,血清CXCL10水平显著下降;严重感染发生在3名患者 (IV CYC) 和1名患者 (TAC) 中.

结论:

与IV CYC和MMF相比,TAcrolimus (TAC) 是一种非劣质的诱导治疗选择,用于狼性炎.
在诱导阶段,TAC提供了与IV CYC和MMF相似的安全概况.
进一步的研究可能会探索长期结果和在LN管理中最佳利用TAC.

关键词:

在CXCL10中,CXCL10是CXCL10中的一个.狼性炎是一种神经炎.诱导疗法是一种诱导疗法.静脉内注射的环酸胺.基酸莫菲蒂尔是什么这就是塔克罗利斯.

更多相关视频

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...